Letter to the Editor

**THAP1** mutations in a Greek primary blepharospasm series

**Keywords:**
THAP1
Blepharospasm
Dystonia
DYT6
Mutations
Phenotype

Benign essential blepharospasm (BEB) is an adult onset focal dystonia that manifests as forced involuntary eyelid closure usually starting between the fifth and the seventh decade [1]. The frequency is rare; affecting around 1 in 20,000 people, where most of the cases are sporadic, approximately 20–30% of patients may have a positive family history, thus indicating a possible genetic contribution in the aetiology of blepharospasm [1].

A recent study examined the genetic influences in blepharospasm based on the examination of patients and their first-degree relatives and found a very high proportion of probands (27%) with at least one first-degree relative affected by some form of focal dystonia [1]. Polymorphisms of the genes encoding TOR1A and D5 dopamine receptor (DRD5) have been associated with an increased lifetime risk of focal dystonia and these genes were investigated in two independent cohorts of Italian and North American patients with blepharospasm [2]. While no association was identified, analysis of the Italian group separately revealed an association with the same TOR1A risk haplotype as previously described in an Icelandic population.

Over the last decade the number of dystonia loci and disease genes have grown dramatically [3]. The focal dystonia group consists of DYT1, DYT4, DYT6 and DYT7 but only three genes have been recognised up to now, TOR1A in DYT1, **THAP1** in DYT6 and CIZ1 recently.

**THAP1** mutations are associated with a number of dystonia phenotypes, variability in severity and progression. In the dystonia cases that have been analysed so far, a handful of dystonia cases have been identified where blepharospasm was part of an overall segmental or generalised dystonia phenotype but no cases with BEB had been reported. Based on the reported data we investigated the role of **THAP1** gene in blepharospasm in a Greek patient series.

All patients and healthy controls that participated in the study gave informed consent and the study was approved by the local ethics committee of the University Hospital in Larissa, Greece. The diagnosis of blepharospasm was based on accepted criteria. Secondary causes such as structural lesions, trauma or exposure to toxic or neuroleptic substances were excluded. All patients were negative for the GAG deletion in the **TOR1A** gene. A total of 70 patients of Greek ancestry were included in this genetic screening study (Table 1). 200 healthy controls were also screened for the **THAP1** gene. Most patients were regularly receiving botulinum toxin.

Standard PCR amplification was carried out as previously described. All patients were screened for mutations in **THAP1** by sequencing.


In the 70 patients screened, 2 patients were found to carry heterozygous **THAP1** variations. The patient with the c.208 A>G (K70E) variation was a 64-year old woman who had blepharospasm since the age of 55 years. Family history was negative for dystonia. This mutation is a missense amino acid change, it is available on-line.

The second patient had a heterozygous **THAP1** intronic variation c.-40T>C was a 75 year old woman who first was diagnosed with blepharospasm at the age of 64. However, 2 years later she developed oromandibular symptoms with spasms of jaw opening. A diagnosis of segmental cranio-cervical dystonia was made at that point. She didn't report positive family history for dystonia. The variation is located in the promoter region 40 bases before the first exon start and therefore it is possible to be implicated in the regulation of gene expression. Both patients were working as farmers and they both reported exposure to pesticides since they were young, for over 30 years.

We sequenced the **THAP1** gene in a cohort of Greek patients with blepharospasm identifying one likely pathogenic mutation and one likely benign intronic variant. The heterozygous missense K70E mutation that we identified is located within the **THAP1**
domain, next to a number of other likely pathogenic THAP1 mutations, these were all absent in controls. The 5′UTR mutation c.-40T>C reported here may contribute to blepharospasm by affecting the secondary structure of mRNA or through other post-transcriptional regulation. This variant is in close proximity to the c.-42C>T variation that has been reported in two unrelated Caucasian women with focal dystonia, one with blepharospasm and the other one with laryngeal dystonia [4]. Both patients were women without positive family history of dystonia, whereas age of disease onset was 62 and 69 years respectively which is quite similar to the age of onset of our patient (64 years). Although UTR and intronic mutations warrant discussion, seem to be frequently associated with the dystonia phenotype and are not present in controls. Disease-associated variants in the 5′UTR of human protein coding genes have been systematically analysed and functionality of these variants correlated highly to predicted secondary structural changes. However, there is still little evidence to suggest that these variants alter the expression or structure of THAP1 gene in dystonia patients.

Prior to this study some other patients with blepharospasm were screened for THAP1 mutations and the two intronic changes discussed above were identified [4]. In addition two cases with blepharospasm as part of a more complex dystonia phenotype with non-synonymous THAP1 mutations were reported. Given the small number of cases screened further analysis of the THAP1 gene is required. As well as THAP1 mutations, blepharospasm can be part of other genetic phenotypes such as Mohr-Tranebjaerg syndrome [5], in general these associations are rare and the aetiology of this type of cranial dystonia remains largely unknown.

Our findings indicate that THAP1 mutations are very rare in this condition but with the advent of rapid genetic screened should be considered in patients, particularly if there is a family history. Further genotype phenotype correlations in THAP1 will be important combined with investigations into the functional consequences of these mutations.

### Financial disclosure

None.

### Conflict of interest

None.

### Acknowledgements

The authors thank the patients and families for their essential contribution to this research. This work was supported by the MRC, the Wellcome Trust, the Brain Research Trust, the Parkinson’s disease foundation and the dystonia medical research foundation (DMRF).

### References


Georgia Xiromerisiou

Department of Molecular Neuroscience and Reta Lila Weston Institute, UCL Institute of Neurology, London, Queen Square, London, United Kingdom

Antonios Petalas, Sophia Tachmitzi

Department of Neurology, Faculty of Medicine University of Thessaly, Larissa, Greece

Efthimios Dardiotis

Department of Neurology, Faculty of Medicine University of Thessaly, Larissa, Greece

Evangelia E. Tsironi

Department of Ophthalmology, University General Hospital of Larissa, University of Thessaly, Larissa, Greece

Georgios Hadjigeorgiou, Styliani Ralli

Department of Neurology, Faculty of Medicine University of Thessaly, Larissa, Greece

Eleanna Kara

Department of Molecular Neuroscience and Reta Lila Weston Institute, UCL Institute of Neurology, London, Queen Square, London, United Kingdom

Antonios Petalas, Sophia Tachmitzi

Department of Ophthalmology, University General Hospital of Larissa, University of Thessaly, Larissa, Greece

John Hardy, Henry Houlden

Department of Molecular Neuroscience and Reta Lila Weston Institute, UCL Institute of Neurology, London, Queen Square, London, United Kingdom

* Corresponding author. Department of Neurology, Faculty of Medicine, University of Thessaly, Biopolis, Mezourlo Hill, 41100 Larissa, Greece. Tel.: +30 241 350 2301; fax: +30 241 350 2300, E-mail address: geoksirom@med.uth.gr (G. Xiromerisiou)

8 June 2012